Genetic associations with valvular calcification and aortic stenosis.

BACKGROUND Limited information is available regarding genetic contributions to valvular calcification, which is an important precursor of clinical valve disease. METHODS We determined genomewide associations with the presence of aortic-valve calcification (among 6942 participants) and mitral annular calcification (among 3795 participants), as detected by computed tomographic (CT) scanning; the study population for this analysis included persons of white European ancestry from three cohorts participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (discovery population). Findings were replicated in independent cohorts of persons with either CT-detected valvular calcification or clinical aortic stenosis. RESULTS One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification (odds ratio per allele, 2.05; P=9.0×10(-10)), a finding that was replicated in additional white European, African-American, and Hispanic-American cohorts (P<0.05 for all comparisons). Genetically determined Lp(a) levels, as predicted by LPA genotype, were also associated with aortic-valve calcification, supporting a causal role for Lp(a). In prospective analyses, LPA genotype was associated with incident aortic stenosis (hazard ratio per allele, 1.68; 95% confidence interval [CI], 1.32 to 2.15) and aortic-valve replacement (hazard ratio, 1.54; 95% CI, 1.05 to 2.27) in a large Swedish cohort; the association with incident aortic stenosis was also replicated in an independent Danish cohort. Two SNPs (rs17659543 and rs13415097) near the proinflammatory gene IL1F9 achieved genomewide significance for mitral annular calcification (P=1.5×10(-8) and P=1.8×10(-8), respectively), but the findings were not replicated consistently. CONCLUSIONS Genetic variation in the LPA locus, mediated by Lp(a) levels, is associated with aortic-valve calcification across multiple ethnic groups and with incident clinical aortic stenosis. (Funded by the National Heart, Lung, and Blood Institute and others.).

[1]  Y. Bossé,et al.  Replication of genetic association studies in aortic stenosis in adults. , 2011, The American journal of cardiology.

[2]  P. Willeit,et al.  Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. , 2011, Journal of the American College of Cardiology.

[3]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[4]  R. Cury,et al.  Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. , 2010, Journal of the American College of Cardiology.

[5]  Marcia M. Nizzari,et al.  Candidate Gene Association Resource (CARe): Design, Methods, and Proof of Concept , 2010, Circulation. Cardiovascular genetics.

[6]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[7]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[8]  W. Paulus,et al.  Aortic stenosis , 2009, The Lancet.

[9]  K. Lunetta,et al.  Methods in Genetics and Clinical Interpretation Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Design of Prospective Meta-Analyses of Genome-Wide Association Studies From 5 Cohorts , 2010 .

[10]  C. Fox,et al.  Defining normal distributions of coronary artery calcium in women and men (from the Framingham Heart Study). , 2008, The American journal of cardiology.

[11]  R. Kronmal,et al.  Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. , 2008, Archives of internal medicine.

[12]  R. Tracy.  ‘Deep phenotyping’: characterizing populations in the era of genomics and systems biology , 2008, Current opinion in lipidology.

[13]  A. Yıldırır,et al.  Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. , 2007, The Journal of heart valve disease.

[14]  P. Donnelly,et al.  A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.

[15]  V. Gudnason,et al.  Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. , 2007, American journal of epidemiology.

[16]  Harlan M Krumholz,et al.  Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. , 2007, JAMA.

[17]  A. Kraja,et al.  Genome-Wide Linkage Mapping for Valve Calcification Susceptibility Loci in Hypertensive Sibships: The Hypertension Genetic Epidemiology Network Study , 2007, Hypertension.

[18]  V. Probst,et al.  Familial Aggregation of Calcific Aortic Valve Stenosis in the Western Part of France , 2006, Circulation.

[19]  D. Srivastava,et al.  Mutations in NOTCH1 cause aortic valve disease , 2005, Nature.

[20]  E. Brilakis,et al.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. , 2005, The New England journal of medicine.

[21]  M. Olivier.  A haplotype map of the human genome. , 2003, Nature.

[22]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[23]  R. Detrano,et al.  Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. , 2005, Radiology.

[24]  B. Horne,et al.  Evidence for a Heritable Component in Death Resulting From Aortic and Mitral Valve Diseases , 2004, Circulation.

[25]  R. Autschbach,et al.  The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. , 2004, European heart journal.

[26]  B. Griffin,et al.  Association Between Apolipoprotein E Alleles and Calcific Valvular Heart Disease , 2003, Circulation.

[27]  R. Lorentzon,et al.  Oestrogen receptor α gene polymorphism is related to aortic valve sclerosis in postmenopausal women , 2003, Journal of internal medicine.

[28]  D. Levy,et al.  Mitral Annular Calcification Predicts Cardiovascular Morbidity and Mortality: The Framingham Heart Study , 2003, Circulation.

[29]  S. Söderbergb,et al.  Lipoprotein(a), Chlamydia pneumoniae , leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis , 2003 .

[30]  I. Kronzon,et al.  The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. , 2002, Archives of internal medicine.

[31]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[32]  D. Grönemeyer,et al.  Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. , 2002, American heart journal.

[33]  David Clayton,et al.  Epidemiological methods for studying genes and environmental factors in complex diseases , 2001, The Lancet.

[34]  F. Ohme,et al.  The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis , 2001, Heart.

[35]  S. Neubauer,et al.  Alterations in myocardial creatinine kinase (CK) and lactate dehydrogenase (LDH) isoenzyme‐distribution in a model of left ventricular dysfunction , 2001, European journal of heart failure.

[36]  G. Porenta,et al.  Predictors of outcome in severe, asymptomatic aortic stenosis , 2001 .

[37]  P. Schnohr.  The Copenhagen City Heart Study : Østerbroundersøgelsen : tables with data from the third examination 1991-1994 , 2001 .

[38]  Bonnie K. Lind,et al.  Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. , 1999, The New England journal of medicine.

[39]  A. Goldberg,et al.  Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. , 1998, The American journal of cardiology.

[40]  Bonnie K. Lind,et al.  Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. , 1997, Journal of the American College of Cardiology.

[41]  C. Otto,et al.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[42]  B. Nordestgaard,et al.  Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. , 1996, Circulation research.

[43]  T. Mitsuhashi,et al.  Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). , 1995, The American journal of cardiology.

[44]  D. Bok,et al.  Lipoprotein (a) displays increased accumulation compared with low-density lipoprotein in the murine arterial wall. , 1994, Chemistry and physics of lipids.

[45]  G. Berglund,et al.  Design and feasibility , 1993 .

[46]  G. Berglund,et al.  The Malmo Diet and Cancer Study. Design and feasibility. , 1993, Journal of internal medicine.

[47]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[48]  A. Scanu,et al.  A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.

[49]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[50]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.